<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594358</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00066787</org_study_id>
    <nct_id>NCT02594358</nct_id>
  </id_info>
  <brief_title>Caffeine in Amblyopia Study</brief_title>
  <acronym>CAS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective data on the visual acuity response in children treated by patching concurrently
      treated with caffeine and estimate the magnitude of effect that might be seen in a randomized
      trial (if no improvement in acuity is seen, this would be sufficient evidence to decide not
      to conduct a randomized, double blind trial).

      Collect prospective data on the tolerability of caffeine in two dosages as an adjuvant
      treatment for amblyopia and provide limited data on its safety.

      Evaluate the potential for a dietary intervention to enhance the acceptance and tolerability
      of patching on the child and family.

      Demonstrate recruitment potential of subjects to participate in a dietary intervention study.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Could not recruit
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quantitative improvement in high resolution visual acuity measured at 3 meters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>A multiquestion survey is adminsitered to the subjects specifically asking about side effects and quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Amblyopia</condition>
  <arm_group>
    <arm_group_label>Caffeine 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patching plus once daily caffeine for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caffeine 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patching plus once daily caffeine for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING</description>
    <arm_group_label>Caffeine 20 mg</arm_group_label>
    <arm_group_label>Caffeine 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Amblyopia from strabismus and amblyopia

        Exclusion Criteria:

          -  Known intolerance to caffeine

          -  Diagnosis and/or treatment of attention deficit/hyperactivity disorder

          -  Presence of an ocular cause for reduced visual acuity

          -  Myopia with a special equivalent -6.00 diopters

          -  Current vision therapy or orthoptics - any type

          -  Ocular cause for reduced visual acuity

          -  Prior intraocular or refractive surgery

          -  History of narrow-angle glaucoma

          -  Strabismus surgery planned within 16 weeks

          -  Nystagmus per se does not exclude the subject if the above visual acuity criteria are
             met

          -  Known skin reactions to patch or bandage adhesives

          -  Known allergy or intolerance to food dyes

          -  Current treatment with topical atropine eyedrops

          -  Menarche, pregnancy or lactation

          -  Use of any of the following medications which may affect caffeine metabolism:
             nafcillin, verapamil, fluvoxamine, ciprofloxacin and other fluoroquinolones,
             modafinil, nafcillin, and omeprazole
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael X Repka, MD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Michael Repka</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Caffeine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

